Rohto Pharmaceutical Co (JP:4527) has released an update.
Rohto Pharmaceutical Co., Ltd. has upwardly revised its consolidated financial forecast for the fiscal year ending March 31, 2025, following the acquisition of Eu Yan Sang International Ltd. and Mono chem-pharm Produkte GmbH. The company projects increased net sales, operating profit, ordinary profit, and profit attributable to owners, leading to a raised year-end dividend forecast from 15.00 to 17.00 yen per share. This positive adjustment reflects Rohto’s commitment to enhancing shareholder returns in line with improved earnings.
For further insights into JP:4527 stock, check out TipRanks’ Stock Analysis page.
